Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

341 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity of pembrolizumab in patients with advanced tumors.
van Vugt MJH, Stone JA, De Greef RHJMM, Snyder ES, Lipka L, Turner DC, Chain A, Lala M, Li M, Robey SH, Kondic AG, De Alwis D, Mayawala K, Jain L, Freshwater T. van Vugt MJH, et al. Among authors: jain l. J Immunother Cancer. 2019 Aug 8;7(1):212. doi: 10.1186/s40425-019-0663-4. J Immunother Cancer. 2019. PMID: 31395089 Free PMC article.
Mechanistic Basis for Maximally Efficacious Dose of Pembrolizumab.
Mayawala K, Nayak T, Jain L, de Alwis D. Mayawala K, et al. Among authors: jain l. Clin Pharmacol Ther. 2022 May;111(5):994. doi: 10.1002/cpt.2492. Epub 2021 Dec 3. Clin Pharmacol Ther. 2022. PMID: 34859427 No abstract available.
Corrigendum to "A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation" [Eur J Canc 131 (2020) 68-75].
Lala M, Li TR, de Alwis DP, Sinha V, Mayawala K, Li M, Yamamoto N, Siu LL, Chartash E, Aboshady H, Jain L. Lala M, et al. Among authors: jain l. Eur J Cancer. 2021 Feb;144:400. doi: 10.1016/j.ejca.2020.12.006. Epub 2021 Jan 4. Eur J Cancer. 2021. PMID: 33414065 No abstract available.
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
Atkins MB, Hodi FS, Thompson JA, McDermott DF, Hwu WJ, Lawrence DP, Dawson NA, Wong DJ, Bhatia S, James M, Jain L, Robey S, Shu X, Homet Moreno B, Perini RF, Choueiri TK, Ribas A. Atkins MB, et al. Among authors: jain l. Clin Cancer Res. 2018 Apr 15;24(8):1805-1815. doi: 10.1158/1078-0432.CCR-17-3436. Epub 2018 Jan 22. Clin Cancer Res. 2018. PMID: 29358500 Clinical Trial.
Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Schalkwijk S, Zhou L, Cohen-Rabbie S, Jain L, Freshwater T, So K, He Z, Gioni I, Tomkinson H, Vishwanathan K, Zhou D. Schalkwijk S, et al. Among authors: jain l. Cancer Chemother Pharmacol. 2021 Aug;88(2):189-202. doi: 10.1007/s00280-021-04274-6. Epub 2021 Apr 26. Cancer Chemother Pharmacol. 2021. PMID: 33903938
341 results